BioCentury
ARTICLE | Clinical News

GL1001: Phase I data

December 22, 2008 8:00 AM UTC

Data from a 14-day, double-blind, placebo-controlled, ascending-dose, U.S. Phase I trial in 32 healthy volunteers showed that multiple doses up to 1,800 mg oral GL1001 were well tolerated with no seri...